NCT04219254 2026-04-15
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
Phase 1/2 Recruiting
BioInvent International AB
University Hospital, Geneva
Centre Oscar Lambret
ImmunOs Therapeutics AG
DualityBio Inc.
3D Medicines
CytomX Therapeutics
Accession Therapeutics Limited
CytomX Therapeutics